Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies (CROSBI ID 297369)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Fabbri, Chiara ; Tansey, Katherine E. ; Perlis, Roy H. ; Hauser, Joanna ; Henigsberg, Neven ; Maier, Wolfgang ; Mors, Ole ; Placentino, Anna ; Rietschel, Marcella ; Souery, Daniel et al. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies // European neuropsychopharmacology, 28 (2018), 8; 945-954. doi: 10.1016/j.euroneuro.2018.05.009

Podaci o odgovornosti

Fabbri, Chiara ; Tansey, Katherine E. ; Perlis, Roy H. ; Hauser, Joanna ; Henigsberg, Neven ; Maier, Wolfgang ; Mors, Ole ; Placentino, Anna ; Rietschel, Marcella ; Souery, Daniel ; Breen, Gerome ; Curtis, Charles ; Lee, Sang-Hyuk ; Newhouse, Stephen ; Patel, Hamel ; O'Donovan, Michael ; Lewis, Glyn ; Jenkins, Gregory ; Weinshilboum, Richard M. ; Farmer, Anne ; Aitchison, Katherine J. ; Craig, Ian ; McGuffin, Peter ; Schruers, Koen ; Biernacka, Joanna M. ; Uher, Rudolf ; Lewis, Cathryn M.

engleski

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies

Cytochrome (CYP) P450 enzymes have a primary role in antidepressant metabolism and variants in these polymorphic genes are targets for pharmacogenetic investigation. This is the first meta- analysis to investigate how CYP2C19 polymorphisms predict citalopram/escitalopram efficacy and side effects. CYP2C19 metabolic phenotypes comprise poor metabolizers (PM), intermediate and intermediate + metabolizers (IM ; IM + ), extensive and extensive + metabolizers (EM [wild type] ; EM + ) and ultra- rapid metabolizers (UM) defined by the two most common CYP2C19 functional polymorphisms (rs4244285 and rs12248560) in Caucasians. These polymorphisms were geno- typed or imputed from genome-wide data in four samples treated with citalopram or escitalo- pram (GENDEP, STAR ∗D, GenPod, PGRN- AMPS). Treatment efficacy was assessed by standardized percentage symptom improvement and by remission. Side effect data were available at weeks 2–4, 6 and 9 in three samples. A fixed- effects meta-analysis was performed using EM as the reference group. Analysis of 2558 patients for efficacy and 2037 patients for side effects showed that PMs had higher symptom improvement (SMD = 0.43, CI = 0.19–0.66) and higher remission rates (OR = 1.55, CI = 1.23–1.96) compared to EMs. At weeks 2–4, PMs showed higher risk of gastro- intestinal (OR = 1.26, CI = 1.08–1.47), neurological (OR = 1.28, CI = 1.07–1.53) and sexual side effects (OR = 1.52, CI = 1.23–1.87 ; week 6 values were similar). No difference was seen at week 9 or in total side effect burden. PMs did not have higher risk of dropout at week 4 compared to EMs. Antidepressant dose was not different among CYP2C19 groups. CYP2C19 polymorphisms may provide helpful information for guiding citalopram/escitalopram treatment, despite PMs being relatively rare among Caucasians ( ∼2%).

CYP2C19 ; Gene ; Antidepressant ; Response ; Side effects ; Major depression

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

28 (8)

2018.

945-954

objavljeno

0924-977X

1873-7862

10.1016/j.euroneuro.2018.05.009

Povezanost rada

Kliničke medicinske znanosti, Temeljne medicinske znanosti

Poveznice
Indeksiranost